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Abstract. Folic acid is frequently given to pregnant women at the same time as intermittent preventive treatment
(IPTp) with sulfadoxine/pyrimethamine (SP), but it is not known if it interferes with the anti-malarial activity of SP. To
investigate this concern, 1,035 Gambian primigravidae were randomized to receive either folic acid (500–1,500 g/day)
together with oral iron (522) or oral iron alone (513) for 14 days at the same time as they received IPTp with SP. On
presentation, 261 women (25%) had Plasmodium falciparum asexual parasitemia. Prevalences of parasitemia on day 14
after treatment were similar in both groups: 5.7% (26 of 458) in the iron plus folic acid group and 4.9% (22 of 446) in
the iron alone group (risk difference 0.74%, 95% confidence interval [CI] −2.2% to 3.7%). Parasitologic cure was
observed in 116 (91%) of 128 of women who were parasitemic on presentation and who received iron and folic acid and
in 122 (92%) of 133 women who received iron alone (difference  1.1%, 95% CI  −5.6% to 8.0%). Women who
received folic acid and iron had a slightly higher mean hemoglobin concentration at day 14 than women who had
received iron alone (difference 0.14 g/dL, 95% CI 0.01–0.27 g/dL). The results of this study suggest that in an area
of low SP resistance, administration of folic acid to pregnant women in a dose of 500–1,500 g/day will not interfere with
the protective effect of SP when used for IPTp.
INTRODUCTION
Malaria adversely affects the outcome of pregnancy for
both the mother and her baby.1 In areas of low transmission,
malaria in pregnancy may result in a severe, acute infection
and even in the death of the mother. In areas of medium or
high transmission, malaria is an important cause of severe
anemia in pregnant women and of low birth weight, both of
which may reduce infant survival.2,3 In areas of medium or
high transmission, many malaria infections during pregnancy
are asymptomatic and difficult to detect and treat. Thus, the
primary public health strategy for controlling malaria in preg-
nancy is prevention. The two main tools used to prevent ma-
laria in pregnancy are insecticide-treated bed nets4 and inter-
mittent preventive treatment (IPTp). The latter, which in-
volves the administration of a full therapeutic dose of an anti-
malarial drug to pregnant women at fixed times during the
course of their pregnancy, regardless of whether they are
known to be infected, is easier to deliver than sustained
chemoprophylaxis and equally effective.5–8 The drug cur-
rently recommended for IPTp is sulfadoxine-pyrimethamine
(SP), a long-acting folate antagonist. How SP achieves its
effect when used for IPTp is uncertain; it is not known if it
acts by clearing established infections intermittently or
whether its prophylactic effect is more important.
In industrialized countries, folic acid supplementation at a
dose of 500 g/day is recommended prior to conception and
in the first trimester of pregnancy to prevent neural tube
defects, and it is given in higher doses to women who have
previously had a baby with a neural tube defect. In develop-
ing countries, folic acid supplementation is used widely in the
second and third trimesters, together with iron, to prevent
nutritional anemia. Folic acid is given to pregnant women
attending antenatal clinics across Africa, including those situ-
ated in areas where malaria is endemic. Because SP exerts its
anti-malarial activity by interfering with the folic acid me-
tabolism of the parasite, concerns have been expressed that
folic acid supplementation of pregnant women at antenatal
clinics could interfere with the ability of SP to provide pro-
tection when used for IPTp because some strains of Plasmo-
dium falciparum can use free folate directly. To investigate
this possibility, we have compared the efficacy of SP when
used for IPTp in Gambian primigravidae who received folic
acid either at the same time as they received IPTp with SP or
two weeks later.
MATERIALS AND METHODS
Study area and population. The study was carried out in 14
mother and child health clinics situated on the north and
south banks of the Gambia River near the town of Farafenni,
The Gambia in the center of the country. In this area, malaria
is highly seasonal with nearly all infections occurring during
the rainy season, which lasts from June to November.9 The
entomologic inoculation rate varies substantially from village
to village but is within the range of 10–50 infectious bites per
year. During an 18-month period from July 2002 to December
2003, primigravidae who attended one of the study clinics
were reviewed as to their eligibility to join the study. Eligi-
bility criteria were pregnancy greater than 15 weeks, hemo-
globin (Hb) concentration > 7g/dL, absence of any serious
underlying disease, absence of a history of an adverse re-
sponse to sulfonamides, and residence in the study area and
willingness to be visited at home.
Recruitment and randomization. If a pregnant woman met
the study entry criteria, written, informed consent to join the
study was obtained and a questionnaire was completed. This
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questionnaire sought information on age, village of residence,
education, socioeconomic status, bed net use, past medical
and obstetric history, and previous treatment during the preg-
nancy. A finger prick blood sample was obtained for deter-
mination of the Hb concentration and for preparation of two
blood films. Provided that the Hb concentration was > 7 g/dL,
the woman was given a study number and SP was adminis-
tered under supervision. The woman was then given the ran-
domization envelope bearing the same study number. This
envelope contained iron and folic acid tablets or iron tablets
alone. Envelopes were pre-packaged by a person who had no
further direct involvement in the trial.
Treatments. All women received directly observed treat-
ment with three tablets of SP (25 mg of pyrimethamine and
500 mg of sulfadoxine) (Cosmos Pharmaceuticals, Nairobi,
Kenya). The content and the solubility of the tablets were
confirmed by high performance liquid chromatography.
Women in the immediate treatment group were then given
iron and folic acid tablets (500 g of folic acid and 47 mg of
ferrous sulfate per tablet) to be taken at home once per day
for 14 days. Women with an Hb concentration of 7–9 g/dL
were asked to take three tablets a day, those with an Hb
concentration of 9–11g/dL were asked to take two tablets a
day, and those with an Hb concentration  11 g/dL were
asked to take one tablet a day in line with routine practice in
The Gambia. Thus, women in this group received 500–1,500
g of folic acid per day. Women in the delayed treatment
group were given oral iron tablets (60 mg of ferrous sulfate
per tablet) to be taken at home once per day for 14 days, 1–3
tablets according to Hb concentration as described above. At
the end of this period, women in this group were given a
supply of iron and folic acid tablets to be taken as described
above for women in the immediate treatment group.
Surveillance. Women were visited at home by a field
worker 14 days after treatment and a finger prick blood
sample was obtained for repeat determination of Hb concen-
tration and for the preparation of two thick blood films. Any
iron or folic acid tablets that had not been used were collected
to measure compliance.
Laboratory methods. Hemoglobin concentration was mea-
sured with a Hemocue device (Hemocue AB, Ängelholm,
Sweden). Thick blood films were stained with Giemsa and
read by two microscopists who were blind to the treatment
code. If results were discrepant, the slide was read by a third
microscopist and the majority view was used for analysis. One
hundred high-power fields were read before a slide was de-
clared negative.
Sample size. The sample size was calculated to be able to
demonstrate that the efficacy of SP was not impaired by tak-
ing folic acid. We anticipated that 5% of the women in the
iron alone group would be parasitemic on day 14 after treat-
ment with SP, and we considered that it would be of clinical
importance if folic acid increased this prevalence to  10%.
For a test of non-inferiority with 90% power, and allowing for
loss to follow-up, 450 women were required in each arm. This
number gave adequate power to compare treatment failure
rates among women who were parasitemic at enrollment, as-
suming an initial prevalence of parasitemia of 30% among
women enrolled.
Data management and statistical methods. After data had
been double entered and verified, the database was locked,
archived at the Medical Research Council (MRC) laborato-
ries, and a copy was sent to the chairman of the study’s Data
Safety Monitoring Board (DSMB). Statistical analyses were
done using STATA version 8 (Stata Corporation, College
Station, TX). The primary trial end point was the prevalence
of P. falciparum asexual stage parasitemia 14 days after treat-
ment. Confidence intervals (CIs) (95% and 99%) were cal-
culated for the difference in parasite prevalence. Since the
study was designed as a non-inferiority trial, conventional
tests of the hypothesis of no treatment effect were not appro-
priate. Effects of covariates (clinic, age, gestational age at
enrollment, ethnic group, educational level, marital status,
and bed net use) were investigated using a generalized linear
model. Parasite prevalence at day 14 in women who had P.
falciparum parasitemia on presentation and an Hb concentra-
tion at day 14 (adjusted for baseline Hb concentration) were
secondary end points.
Ethics. The trial was reviewed and approved by the Gam-
bia Government/MRC and London School of Hygiene and
Tropical Medicine ethics committees. The study design was
reviewed and approved by a DSMB that monitored the
course of the study and approved the analytical plan.
RESULTS
Trial profile. A total of 1,687 women were screened, of
whom 1,035 were recruited and randomized to receive either
early (522) or delayed (513) folic acid supplementation (Fig-
ure 1). The main reason for initial exclusion from the study
FIGURE 1. Trial profile.
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was residence in neighboring Senegal. Senegalese women are
reluctant to cross the border for repeated clinic visits and it
was thought best to exclude them before entry into the trial.
Sixty-two women (12%) in the early supplementation group
and 64 (12%) in the delayed supplementation group were lost
to follow-up, mainly because of their travel outside the study
area. Comparison of baseline characteristics showed no sig-
nificant differences between defaulters and those who were
seen on day 14. The characteristics of women allocated to
each of the study groups are shown in Table 1. The two treat-
ment groups were similar with respect to baseline character-
istics. To check compliance with treatment, blister packs ob-
tained from 794 women were inspected; 71% had no leftover
medication (69% [282 of 406] in the early supplementation
group and 73% [283 of 388] in the delayed supplementation
group).
Response to treatment with SP. Overall, 261 (29%) of 904
women were parasitemic at enrollment. The prevalence of
parasitemia at enrollment increased during the transmission
season from 18% in July to 45% in December and then de-
creased during the following dry season. On day 14 after
treatment with SP, the prevalence of P. falciparum asexual
stage parasitemia (regardless of whether parasites were
present on day 0) was 26 (5.7%) of 458 in the early supple-
mentation group and 22 (4.9%) of 446 in the delayed supple-
mentation group (risk difference 0.74%, 95% CI −2.2%
to 3.7% and 99% CI  −3.1% to 4.6%, P  0.61). Results
were similar when the number of tablets of folic acid taken
was taken into account. In the subgroup of women who re-
ceived three tablets per day, the prevalence of parasitemia on
day 14 was 6.5% in the early folic acid supplementation group
and 8.4% in the delayed supplementation group. Parasite
clearance rates were similar in the two groups. Among
women who were parasitemic at enrollment, 116 (91%) of 128
women in the early supplementation group no longer had
asexual stage P. falciparum parasitemia at day 14 compared
with 122 (92%) of 133 women in the delayed supplementation
group, which is a difference of 1.1% (95% CI  −5.6% to
8.0%, P  0.75). Among women who received three tablets
per day, the percentages were 88% and 91%, respectively.
Season did not influence the interaction between SP and folic
acid.
Effect of folic acid supplementation on Hb concentra-
tion. Hemoglobin concentration was measured on days 0 and
14 in 886 women. On presentation, Hb concentrations in
women in the early and delayed supplementation groups were
9.68 g/dL and 9.61 g/dL, respectively. However, at day 14,
women in the early folic acid supplementation group had a
slightly higher mean Hb concentration than women in the
delayed supplementation group (9.76 g/dL versus 9.68 g/dL).
Adjusting for differences in the baseline Hb concentration,
the early supplementation group still had a slightly higher
mean Hb concentration, a difference of 0.14 g/dL (95% CI
0.01–0.270, P  0.04). The difference in Hb concentration
was slightly greater among women who received higher dose
of folic acid but this interaction was not statistically signifi-
cant.
DISCUSSION
Although SP and folic acid are now given concurrently to
pregnant women in clinics across Africa, it is not known
whether co-administration of folic acid interferes with the
anti-malarial activity of SP when used for IPTp. We are not
aware of any previous study that has addressed this issue
directly. On the Thailand/Myanmar border, recent prior
supplementation with iron and folic acid was a risk factor for
an episode of P. vivax malaria but not for P. falciparum in-
fections.10
A small number of studies have looked for evidence of an
interaction between folic acid and SP when these drugs have
been used together in the management of children with acute
malaria. In a study undertaken in The Gambia, the parasite
failure rate at day 14 after treatment with SP was higher in
children who had received concurrent treatment with folic
acid than in those who had not.11 In this study, a relatively
large dose of 5 mg of folic acid per day was given. In Kenya,
subjects with clinical malaria (mean age  80 months) who
received 2.5–5 mg of folic acid at the time of treatment with
SP cleared parasites more slowly than patients in the control
group during the first week after treatment, but subsequently
the rate of parasite clearance was similar in the two groups.
Folic acid treatment did not effect the clinical cure rate.12
Similar results were obtained in Zambia. In this study of chil-
dren with acute malaria treated with SP, the prevalence of
parasitemia was significantly higher in those who had daily
supplementation with 1 mg of folic acid per day for 14 days
than in those who received placebo at day 3 after the start of
treatment but not at days 14 or 28 (Mulenga M, 2003. A
randomised controlled trial of atovaquone/proguanil versus
sulfadoxine/pyrimethamine, with or without folic acid supple-
mentation, in the treatment of severe Plasmodium falciparum
malarial anaemia. PhD thesis. University of London, London,
United Kingdom). The results of these studies indicate that,
in children, administration of folic acid at the time of treat-
ment with SP does have some inhibitory effect on parasite
clearance, which is most marked in the first week after treat-
ment.
TABLE 1
Baseline characteristics of the women at enrollment
Early folic acid
supplementation
(n  522)
Late folic acid
supplementation
(n  513)
Age (years)
15–19 299 (61%) 298 (60%)
20–29 190 (39%) 188 (38%)
 30 1 (0.2%) 4 (0.8%)
Education, highest level
attained
No formal education 54 (10%) 45 (9%)
Madrassa (Islamic
school) 366 (70%) 364 (71%)
Primary 40 (8%) 38 (7%)
Secondary or higher 61 (12%) 65 (13%)
Ethnic group
Mandinka 244 (47%) 235 (46%)
Fula 127 (24%) 133 (26%)
Wolof 114 (22%) 115 (23%)
Other 37 (7%) 28 (5%)
Mean hemoglobin at
enrollment (range)
(g/DL) 9.73 (6.1–15.8) 9.64 (6.3–14.3)
Plasmodium falciparum
prevalence (asexual
stages) 144/520 (28%) 150/510 (29%)
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We did not find any reduction in the parasitologic cure rate
in primigravidae who received folic acid supplementation to-
gether with SP. There are a number of possible reasons for
this finding. First, parasite prevalence was measured only at
day 14 after treatment and not earlier as in the pediatric
studies, the results of which were not known at the time that
this trial was started. Thus, an early delay in parasite clear-
ance may have been missed. Second, the dose of folic acid
received by the primigravidae in this study (500–1,500 g/
day) was proportionally much less than that used in the pe-
diatric studies and may have produced smaller increases in
plasma and red blood cell folate concentrations. Finally, the
sample size was relatively small and a small effect of folic acid
could have been missed. However, the study was adequately
powered to rule out anything more than a 5% increase in
parasite prevalence at day 14 after the start of treatment.
The study was conducted in an area where the prevalence
of P. falciparum resistance to SP is moderate. This is indicated
by the fact that the day 14 parasitologic cure in the study
women was greater than 90% and by the results of a trial
conducted in children with clinical malaria in the same area in
the year prior to the current study (Dunyo S and others,
unpublished data). In this pediatric trial, the prevalence of
parasitologic failure at day 28 after treatment with SP was 6%
after correction by polymerase chain reaction for re-
infections and 18% overall. The prevalence in pre-treatment
samples of the triple mutations in the dihydrofolate reductase
gene (positions 51, 59, and 108) associated with resistance to
pyrimethamine was 67% and that of the mutation at position
437 in the dihydropteroate synthetase gene associated with
resistance to sulfonamides was 49%. In many areas of east
Africa, levels of resistance to SP are much higher than found
in the Farafenni study area, and it is possible that in such
communities the inhibitory effect of folic acid supplementa-
tion on the effectiveness of SP might be more marked. Iso-
lates of P. falciparum vary in their ability to use exogenous
folate and parasites with a higher propensity to do this might
be able to make better use of the higher plasma concentra-
tions provided through folic acid supplementation.13 How-
ever, it is unlikely that the doses of folic acid usually used in
pregnancy would have a major effect on plasma or red blood
cell folate concentrations.
Supplementation with folic acid is given widely in antenatal
clinics throughout Africa to prevent anemia, but there is lim-
ited evidence of its efficacy in improving the Hb concentra-
tion when used in this way, in contrast to the impact of iron.
There appear to be major geographic differences within Af-
rica in the importance of folic acid deficiency as a cause of
anemia in pregnancy. In western Nigeria it is a major cause,14
but in coastal Kenya, only a few primigravidae had sub-
normal folate levels.15 However, assessment of folate defi-
ciency in areas where malaria is prevalent is complicated by
the fact that malaria increases red blood cell folate concen-
tration, perhaps by increasing the proportion of circulating
reticulocytes that contain a higher concentration of folate
than mature red blood cells.15 Folic acid did not increase the
Hb concentration in supplementation studies in Uganda and
Nigeria, in contrast to anti-malarial drugs.16,17 Thus, we were
surprised to find a small but statistically significant difference
in Hb concentrations between women who took folic acid
supplementation for 14 days compared with those who did
not. This suggested that some were folate deficient and had
benefited from this intervention. However, since the differ-
ence between groups was small, it may have been a chance
finding and it is unlikely to be clinically important.
Overall, the results of this study are reassuring. Folic acid
supplementation did not increase the risk of parasitologic fail-
ure in asymptomatic primigravidae given IPTp with SP. How-
ever, these results need confirmation in an area where the
prevalence of resistance to SP is higher than in The Gambia,
and the effect of folic acid on the rate of clearance of parasites
by women given SP merits further study.
Received August 19, 2005. Accepted for publication February 23,
2006.
Acknowledgments: We thank the women who agreed to participate
in this study. We also thank Sana Jawara (Divisional Health Office,
Lower River Division); field supervisors Fabakaray Sanyang, Momo-
dou Jobe, and Faramba Ceesay; and the many field assistants and
laboratory staff who contributed to the trial; the members of the
DSMB (Dr. Aggrey Oloo, Professor B. J. Brabin, Dr. K. Bojang, and
Dr. D. M. Schellenberg) for their help with the project; and Dr.
Harparkash Kaur for undertaking the high-performance liquid chro-
matography analyses. The support of Margaret Pinder in the super-
vision of laboratory staff and the support of the administrative staff of
the MRC Laboratories (Banjul, The Gambia) is gratefully acknowl-
edged.
Financial support: This study was supported by the Medical Research
Council and the Gates Malaria Partnership, which receives funding
from the Bill & Melinda Gates Foundation.
Authors’ addresses: Amadou Mbaye, Sam Dunyo, and Gijs Wal-
raven, Medical Research Council Laboratories, Banjul, The Gambia.
Keshena Richardson, Caroline Shulman, Paul Milligan, and Brian
Greenwood, Department of Infectious and Tropical Diseases. Lon-
don School of Hygiene and Tropical Medicine, Keppel Street, Lon-
don WC1E 7HT, United Kingdom. Baba Balajo, Department of
Health, The Government of The Gambia, Banjul, The Gambia.
REFERENCES
1. Brabin BJ, 1991. The risk and severity of malaria in pregnant
women. Applied Field Research in Malaria Reports 1. Geneva:
World Health Organization.
2. Menendez C, 1995. Malaria during pregnancy: a priority area of
malaria research and control. Parasitol Today 2: 178–183.
3. Guyatt HL, Snow RW, 2001. Malaria in pregnancy as an indirect
cause of infant mortality in sub-Saharan Africa. Trans R Soc
Trop Med Hyg 95: 569–576.
4. ter Kuile FO, Terlouw DJ, Phillips-Howard PA, Hawley WA,
Friedman JF, Kariuki SK, Shi YP, Kolczak MS, Lal AA, Vu-
lule JM, Nahlen BL, 2003. Reduction of malaria during preg-
nancy by permethrin-treated bed nets in an area of intense
perennial malaria transmission in Western Kenya. Am J Trop
Med Hyg 68 (Suppl 4): 50–60.
5. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitsulo I,
Wirima JJ, 1994. The efficacy of antimalarial regimens con-
taining sulfadoxine-pyrimethamine and/or chloroquine in pre-
venting peripheral and placental Plasmodium falciparum in-
fection amongst pregnant women in Malawi. Am J Trop Med
Hyg 51: 515–522.
6. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore
A, Muga R, Oloo AJ, Steketee RW, 1998. Efficacy of sulfa-
doxine pyrimethamine for prevention of placental malaria in
an area of Kenya with a high prevalence of malaria and human
immunodeficiency virus infection. Am J Trop Med Hyg 59:
813–822.
7. Shulman CE, Dorman EK, Cutts F, Kawuondo K, Bulmer JN,
Peshu N, Marsh K, 1998. Intermittent sulphadoxine-
pyrimethamine to prevent severe anaemia secondary to ma-
laria in pregnancy: a randomised placebo-controlled trial. Lan-
cet 353: 632–636.
8. Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C,
FOLIC ACID SUPPLEMENTATION IN PRIMIGRAVIDAE 963
Molyneux ME, 2000. Intermittent sulfadoxine-pyrimethamine
in pregnancy: effectiveness against malaria morbidity in Blan-
tyre, Malawi, in 1997–1999. Trans R Soc Trop Med Hyg 94:
549–553.
9. Greenwood BM, Bradley AK, Greenwood AM, Byass P, Jam-
meh K, Marsh K, Tulloch S, Oldfield FSJ, Hayes R, 1987.
Mortality and morbidity from malaria among children in a
rural area of the Gambia, West Africa. Trans R Soc Trop Med
Hyg 81: 478–486.
10. Nacher M, McGready R, Stepniewska K, Cho T, Looareesuwan
S, White NJ, Nosten F, 2003. Haematinic treatment of anaemia
increases the risk of Plasmodium vivax malaria in pregnancy.
Trans R Soc Trop Med Hyg 97: 273–276.
11. Boele van Hensbroek M, Morris-Jones S, Meisner S, Jaffar SB,
Dackour R, Phillips C, Greenwood BM, 1995. Iron, but not
folic acid, combined with effective antimalarial therapy pro-
motes haematological recovery in African children with acute
falciparum malaria. Trans R Soc Trop Med Hyg 89: 672–676.
12. Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJD,
Watkins WM, 2005. Folic acid supplementation reduces the
efficacy of antifolate antimalarial therapy. Am J Trop Med
Hyg 73: 166–170.
13. Hyde JE, 2005. Exploring the folate pathway in Plasmodium fal-
ciparum. Acta Trop 94: 191–206.
14. Fleming AF, 1989. Tropical obstetrics and gynaecology. 1. Anae-
mia in pregnancy in tropical Africa. Trans R Soc Trop Med
Hyg 83: 441–448.
15. Shulman CE, Graham WJ, Jilo H, Lowe BS, New L, Obiero J,
Snow RW, Marsh K, 1996. Malaria is an important cause of
anaemia in primigravidae: evidence from a district hospital in
Kenya. Trans R Soc Trop Med Hyg 90: 535–539.
16. Hamilton PJS, Gebbie DAM, Wilks NE, Lothe F, 1972. The role
of malaria, folic acid deficiency and haemoglobin AS in preg-
nancy at Mulago Hospital. Trans R Soc Trop Med Hyg 66:
594–602.
17. Fleming AF, Ghatoura GBS, Harrison KA, Briggs ND, Dunn
DT, 1986. The prevention of anaemia in pregnancy in primi-
gravidae in the guineas savanna of Nigeria. Ann Trop Med
Parasitol 80: 211–233.
MBAYE AND OTHERS964
